Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$3.77 USD
-0.08 (-2.08%)
Updated May 17, 2024 04:00 PM ET
After-Market: $3.80 +0.03 (0.80%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALRN 3.77 -0.08(-2.08%)
Will ALRN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALRN
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now
ALRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock
Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for ALRN
Aileron Therapeutics Announces New Interim CFO Appointment
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
ALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024
Aileron Therapeutics GAAP EPS of -$0.86 beats by $0.16
Aileron Therapeutics to Present at Two Upcoming Investor Conferences